{"nctId":"NCT00104676","briefTitle":"Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors","startDateStruct":{"date":"2003-11-26","type":"ACTUAL"},"conditions":["Extragonadal Germ Cell Tumor","Teratoma","Testicular Germ Cell Tumor"],"count":263,"armGroups":[{"label":"Arm I","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: bleomycin sulfate","Drug: cisplatin","Drug: etoposide"]},{"label":"Arm II","type":"EXPERIMENTAL","interventionNames":["Biological: bleomycin sulfate","Drug: cisplatin","Drug: etoposide","Drug: ifosfamide","Drug: oxaliplatin","Drug: paclitaxel"]}],"interventions":[{"name":"bleomycin sulfate","otherNames":[]},{"name":"cisplatin","otherNames":[]},{"name":"etoposide","otherNames":[]},{"name":"ifosfamide","otherNames":[]},{"name":"oxaliplatin","otherNames":[]},{"name":"paclitaxel","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Diagnosis of non-seminomatous germ cell tumors (NSGCT) as evidenced by 1 of the following criteria:\n\n  * Histologically confirmed NSGCT\n  * Clinical evidence of disease AND high serum human chorionic gonadotropin (HCG) or alpha-fetoprotein (AFP) levels\n* Clinical stage II-III disease (disseminated disease)\n* Testicular, retroperitoneal, or mediastinal primary site\n* Poor prognosis disease, meeting 1 of the following criteria:\n\n  * Mediastinal primary site\n  * Non-pulmonary visceral metastases\n  * One of the following lab values:\n\n    * HCG \\> 50,000 UI/L\n    * AFP \\> 10,000 ng/mL\n    * Lactate dehydrogenase \\> 10 times upper limit of normal (ULN)\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* Over 16\n\nPerformance status\n\n* Not specified\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Absolute granulocyte count ≥ 1,500/mm\\^3\n* Platelet count ≥ 100,000/mm\\^3\n\nHepatic\n\n* Bilirubin ≤ 1.5 times ULN\n\nRenal\n\n* Creatinine clearance \\> 60 mL/min\n\nOther\n\n* No other prior malignancy except basal cell skin cancer\n* No HIV positivity\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* No prior chemotherapy\n\nEndocrine therapy\n\n* Not specified\n\nRadiotherapy\n\n* Not specified\n\nSurgery\n\n* Not specified","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"120 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival Rate After 1 Course of Treatment","description":"Primary objective is to compare the progression-free survival of participants after 1 cycle of treatment, treated randomly by 3 additional cycles of BEP (Arm I) or by T-BEP-Oxaliplatin/cisplatin-ifosfamide-Bleomycin (Arm II). The median progression-free survival rate was defined as the median percentage of participants alive without disease progression after 1 course of treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"To evaluated the overall survival in both groups in participants presenting fast and slow decrease in serum levels of tumor markers. The median overall survival was defined as the median percentage of participants alive after 1 course of treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"73","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":37,"n":98},"commonTop":["Hemoglobin","Asthenia","Nausea","Granulocytes","Platelets"]}}}